# How GLP-1 Medications Work in Weight Management

GLP-1 medications affect appetite, blood glucose, and digestion. Understand the mechanism without mistaking it for a promised result.

Canonical: https://velri.co/blog/how-glp-1-medications-work-weight-management
Publisher: Velri (https://velri.co/about)
Published: 2026-06-14
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

GLP-1 is a hormone involved in appetite and glucose regulation. Medications that activate its receptor can reduce food intake through effects on appetite, while also changing how the body manages blood glucose.[1]

## Appetite and glucose are connected effects

Semaglutide activates the GLP-1 receptor. The approved medication increases insulin secretion and reduces glucagon secretion in a glucose-dependent manner. Insulin helps manage glucose, while glucagon signals the body to increase glucose availability.[1]

Its weight-management effect also involves reduced calorie intake. Feeling less hungry is part of the intended action, although the experience varies between people.

## Digestion changes too

Semaglutide delays gastric emptying, which means food leaves the stomach more slowly. Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are among its common adverse reactions.[1]

Digestive symptoms are not a measure of how well treatment is working. Persistent symptoms that interfere with eating or drinking belong in the treatment review.

## Why tirzepatide is described differently

Tirzepatide acts at both GIP and GLP-1 receptors. GIP is another hormone signal involved in glucose regulation. This dual action distinguishes its mechanism from a medication acting only at GLP-1 receptors.[2]

 Suitability and response depend on the specific medication, health history, tolerability, and treatment course.

## The product still matters

Prescribing information and trials describe particular FDA-approved products. Compounded semaglutide and tirzepatide are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before marketing.[3]

A discussion about treatment should identify the exact preparation and the medical reason for considering it.

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support